Aspire Biopharma Holdings Inc. (Nasdaq: ASBP) has announced a $21 million private placement through a securities purchase agreement with select institutional and accredited investors. The agreement, signed on February 6, 2026, involves the purchase and sale of up to 26,250 shares. This move is aimed at strengthening the company’s balance sheet, enhancing its capital position, and fortifying shareholder equity to meet Nasdaq requirements.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aspire Biopharma Holdings Inc. published the original content used to generate this news brief on February 11, 2026, and is solely responsible for the information contained therein.